Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Boston Scientific Corp., consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Current debt obligations	20)	261)	13)	1,416)	2,253)
Accounts payable	862)	794)	513)	542)	349)
Legal reserves	231)	264)	505)	470)	712)
Payroll and related liabilities	830)	848)	681)	708)	630)
Rebates	352)	350)	331)	298)	229)
Contingent consideration	74)	289)	26)	56)	138)
Other	673)	685)	654)	577)	537)
Accrued expenses	2,160)	2,436)	2,197)	2,109)	2,246)
Deferred revenue	220)	208)	138)	144)	115)
Licensing arrangements	79)	138)	153)	197)	—)
Taxes payable	232)	209)	158)	265)	125)
Liabilities held for sale	—)	—)	200)	—)	—)
Other	230)	228)	309)	193)	172)
Other current liabilities	761)	783)	958)	799)	412)
Current liabilities	3,803)	4,274)	3,681)	4,866)	5,260)
Long-term debt	8,915)	8,804)	9,130)	8,592)	4,803)
Deferred tax liabilities	144)	310)	330)	595)	328)
Accrued income taxes	597)	442)	547)	667)	739)
Legal reserves	212)	284)	64)	227)	217)
Contingent consideration	75)	197)	171)	299)	209)
Licensing arrangements	80)	143)	253)	374)	—)
Long-term operating lease liabilities	347)	389)	401)	276)	—)
Deferred revenue	289)	276)	257)	257)	—)
Other	434)	489)	617)	535)	717)
Other long-term liabilities	2,034)	2,220)	2,310)	2,635)	1,882)
Long-term liabilities	11,093)	11,334)	11,770)	11,822)	7,013)
Total liabilities	14,896)	15,608)	15,451)	16,688)	12,273)
Preferred stock, $0.01 par value	—)	—)	—)	—)	—)
Common stock, $0.01 par value	17)	17)	17)	16)	16)
Treasury stock, at cost	(2,251)	(2,251)	(2,251)	(1,717)	(1,717)
Additional paid-in capital	20,288)	19,985)	19,731)	17,561)	17,347)
Accumulated deficit	(750)	(1,392)	(2,378)	(2,253)	(6,953)
Accumulated other comprehensive income, net of tax	269)	263)	207)	270)	33)
Stockholders’ equity	17,573)	16,622)	15,326)	13,877)	8,726)
Total liabilities and stockholders’ equity	32,469)	32,230)	30,777)	30,565)	20,999)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Download chart

Balance sheet item	Description	The company
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Boston Scientific Corp. current liabilities increased from 2020 to 2021 but then slightly decreased from 2021 to 2022 not reaching 2020 level.
Long-term liabilities	Amount of obligation due after one year or beyond the normal operating cycle, if longer.	Boston Scientific Corp. long-term liabilities decreased from 2020 to 2021 and from 2021 to 2022.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Boston Scientific Corp. total liabilities increased from 2020 to 2021 but then decreased significantly from 2021 to 2022.
Stockholders’ equity	Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.	Boston Scientific Corp. stockholders’ equity increased from 2020 to 2021 and from 2021 to 2022.

Boston Scientific Corp. (NYSE:BSX)

Balance Sheet: Liabilities and Stockholders’ Equity